Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,1576053,area under the saliva flow-time curves,"2. Pirenzepine significantly reduced the area under the saliva flow-time curves (7.29 +/- 3.30 g min-1 h without pirenzepine; 4.19 +/- 2.59 g min-1 h with pirenzepine, P less than 0.01).",The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576053/),[g·h] / [min],7.29,15248,DB00670,Pirenzepine
,1576053,area under the saliva flow-time curves,"2. Pirenzepine significantly reduced the area under the saliva flow-time curves (7.29 +/- 3.30 g min-1 h without pirenzepine; 4.19 +/- 2.59 g min-1 h with pirenzepine, P less than 0.01).",The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576053/),[g·h] / [min],4.19,15249,DB00670,Pirenzepine
,1576053,Cmax,"Pirenzepine had no significant effect on plasma paracetamol Cmax (17.5 +/- 7.8 micrograms ml-1 without pirenzepine; 12.6 +/- 7.7 micrograms ml-1 with pirenzepine), plasma tmax (0.2 h (0.2-0.8 h) without pirenzepine; (0.2 h 0.2-0.8 h) with pirenzepine) and plasma AUC(0.6 h) (32.3 +/- 7.2 micrograms ml-1 h without pirenzepine; 30.3 +/- 6.5 micrograms ml-1 h with pirenzepine).",The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576053/),[μg] / [ml],17.5,15250,DB00670,Pirenzepine
,1576053,Cmax,"Pirenzepine had no significant effect on plasma paracetamol Cmax (17.5 +/- 7.8 micrograms ml-1 without pirenzepine; 12.6 +/- 7.7 micrograms ml-1 with pirenzepine), plasma tmax (0.2 h (0.2-0.8 h) without pirenzepine; (0.2 h 0.2-0.8 h) with pirenzepine) and plasma AUC(0.6 h) (32.3 +/- 7.2 micrograms ml-1 h without pirenzepine; 30.3 +/- 6.5 micrograms ml-1 h with pirenzepine).",The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576053/),[μg] / [ml],12.6,15251,DB00670,Pirenzepine
,1576053,plasma tmax,"Pirenzepine had no significant effect on plasma paracetamol Cmax (17.5 +/- 7.8 micrograms ml-1 without pirenzepine; 12.6 +/- 7.7 micrograms ml-1 with pirenzepine), plasma tmax (0.2 h (0.2-0.8 h) without pirenzepine; (0.2 h 0.2-0.8 h) with pirenzepine) and plasma AUC(0.6 h) (32.3 +/- 7.2 micrograms ml-1 h without pirenzepine; 30.3 +/- 6.5 micrograms ml-1 h with pirenzepine).",The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576053/),h,0.2,15252,DB00670,Pirenzepine
,1576053,plasma AUC,"Pirenzepine had no significant effect on plasma paracetamol Cmax (17.5 +/- 7.8 micrograms ml-1 without pirenzepine; 12.6 +/- 7.7 micrograms ml-1 with pirenzepine), plasma tmax (0.2 h (0.2-0.8 h) without pirenzepine; (0.2 h 0.2-0.8 h) with pirenzepine) and plasma AUC(0.6 h) (32.3 +/- 7.2 micrograms ml-1 h without pirenzepine; 30.3 +/- 6.5 micrograms ml-1 h with pirenzepine).",The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576053/),[h·μg] / [ml],0.6,15253,DB00670,Pirenzepine
,1576053,plasma AUC,"Pirenzepine had no significant effect on plasma paracetamol Cmax (17.5 +/- 7.8 micrograms ml-1 without pirenzepine; 12.6 +/- 7.7 micrograms ml-1 with pirenzepine), plasma tmax (0.2 h (0.2-0.8 h) without pirenzepine; (0.2 h 0.2-0.8 h) with pirenzepine) and plasma AUC(0.6 h) (32.3 +/- 7.2 micrograms ml-1 h without pirenzepine; 30.3 +/- 6.5 micrograms ml-1 h with pirenzepine).",The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576053/),[h·μg] / [ml],32.3,15254,DB00670,Pirenzepine
,1576053,plasma AUC,"Pirenzepine had no significant effect on plasma paracetamol Cmax (17.5 +/- 7.8 micrograms ml-1 without pirenzepine; 12.6 +/- 7.7 micrograms ml-1 with pirenzepine), plasma tmax (0.2 h (0.2-0.8 h) without pirenzepine; (0.2 h 0.2-0.8 h) with pirenzepine) and plasma AUC(0.6 h) (32.3 +/- 7.2 micrograms ml-1 h without pirenzepine; 30.3 +/- 6.5 micrograms ml-1 h with pirenzepine).",The effect of pirenzepine on gastric emptying and salivary flow rate: constraints on the use of saliva paracetamol concentrations for the determination of paracetamol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1576053/),[h·μg] / [ml],30.3,15255,DB00670,Pirenzepine
,9010634,radiocarbon recovery,"Mean radiocarbon recovery was approximately 87%, with 30% appearing in the faces and 57% excreted in the urine.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),%,87,23947,DB00670,Pirenzepine
,9010634,radiocarbon recovery,"Mean radiocarbon recovery was approximately 87%, with 30% appearing in the faces and 57% excreted in the urine.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),%,30,23948,DB00670,Pirenzepine
,9010634,radiocarbon recovery,"Mean radiocarbon recovery was approximately 87%, with 30% appearing in the faces and 57% excreted in the urine.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),%,57,23949,DB00670,Pirenzepine
,9010634,peak plasma concentration,"Mean peak plasma concentration of OLZ was 11 ng/ml, whereas that of radioactivity was 39 ng eq/ml.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),[ng] / [ml],11,23950,DB00670,Pirenzepine
,9010634,peak plasma concentration,"Mean peak plasma concentration of OLZ was 11 ng/ml, whereas that of radioactivity was 39 ng eq/ml.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),[eq·ng] / [ml],39,23951,DB00670,Pirenzepine
,9010634,plasma terminal elimination half-lives,"Mean plasma terminal elimination half-lives were 27 and 59 hr, respectively, for OLZ and total radioactivity.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),h,27,23952,DB00670,Pirenzepine
,9010634,plasma terminal elimination half-lives,"Mean plasma terminal elimination half-lives were 27 and 59 hr, respectively, for OLZ and total radioactivity.",Disposition and biotransformation of the antipsychotic agent olanzapine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010634/),h,59,23953,DB00670,Pirenzepine
,10870093,terminal half-life,The terminal half-life of olanzapine in plasma was 2.5 h and in tissues it ranged from 3 to 5.2 h.,Pharmacokinetics and tissue distribution of olanzapine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870093/),h,2.5,28115,DB00670,Pirenzepine
,10870093,terminal half-life,The terminal half-life of olanzapine in plasma was 2.5 h and in tissues it ranged from 3 to 5.2 h.,Pharmacokinetics and tissue distribution of olanzapine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870093/),h,3 to 5.2,28116,DB00670,Pirenzepine
,6894697,half-lives,"After a single i.v. injection of the drug (2 mg/kg), the concentration of radioactivity in the blood decreased bi-phasically with half-lives of 1 and 8 h.","Absorption, distribution and excretion of 14C-pirenzepine in rats. Accumulation characteristics after multiple dose regimen. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6894697/),h,1,54529,DB00670,Pirenzepine
,6894697,half-lives,"After a single i.v. injection of the drug (2 mg/kg), the concentration of radioactivity in the blood decreased bi-phasically with half-lives of 1 and 8 h.","Absorption, distribution and excretion of 14C-pirenzepine in rats. Accumulation characteristics after multiple dose regimen. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6894697/),h,8,54530,DB00670,Pirenzepine
,6894697,excreted,The drug found excreted into urine was about 46% and into feces about 53% of the administered dose 96 h after i.v. injection.,"Absorption, distribution and excretion of 14C-pirenzepine in rats. Accumulation characteristics after multiple dose regimen. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6894697/),%,46,54531,DB00670,Pirenzepine
,6894697,urinary excretion,"After single oral administration, urinary excretion was found extremely low, i.e., 8%, while 91% was excreted via feces.","Absorption, distribution and excretion of 14C-pirenzepine in rats. Accumulation characteristics after multiple dose regimen. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6894697/),%,8,54532,DB00670,Pirenzepine
,6894697,urinary excretion,"After single oral administration, urinary excretion was found extremely low, i.e., 8%, while 91% was excreted via feces.","Absorption, distribution and excretion of 14C-pirenzepine in rats. Accumulation characteristics after multiple dose regimen. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6894697/),%,91,54533,DB00670,Pirenzepine
,11499485,signal:noise,"The limit of detection of the assay (signal:noise=3:1) and the lower limit of quantitation were 0.75 ng and 1 ng/ml of olanzapine, respectively.",A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499485/),,3:1,63311,DB00670,Pirenzepine
,11499485,signal:noise,"The limit of detection of the assay (signal:noise=3:1) and the lower limit of quantitation were 0.75 ng and 1 ng/ml of olanzapine, respectively.",A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499485/),ng,0.75,63312,DB00670,Pirenzepine
,11499485,recoveries,"The recoveries of olanzapine (50 ng/ml) and the internal standard were 83 +/- 6 and 92 +/- 6% in plasma, respectively, and 79 +/- 7 and 89 +/- 7% in urine, respectively.",A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499485/),%,83,63313,DB00670,Pirenzepine
,11499485,recoveries,"The recoveries of olanzapine (50 ng/ml) and the internal standard were 83 +/- 6 and 92 +/- 6% in plasma, respectively, and 79 +/- 7 and 89 +/- 7% in urine, respectively.",A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499485/),%,92,63314,DB00670,Pirenzepine
,11499485,recoveries,"The recoveries of olanzapine (50 ng/ml) and the internal standard were 83 +/- 6 and 92 +/- 6% in plasma, respectively, and 79 +/- 7 and 89 +/- 7% in urine, respectively.",A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499485/),%,79,63315,DB00670,Pirenzepine
,11499485,recoveries,"The recoveries of olanzapine (50 ng/ml) and the internal standard were 83 +/- 6 and 92 +/- 6% in plasma, respectively, and 79 +/- 7 and 89 +/- 7% in urine, respectively.",A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499485/),%,89,63316,DB00670,Pirenzepine
,11499485,Accuracy,"Accuracy was 96% and 93% at 50 and 1 ng/ml, respectively.",A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499485/),%,96,63317,DB00670,Pirenzepine
,11499485,Accuracy,"Accuracy was 96% and 93% at 50 and 1 ng/ml, respectively.",A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499485/),%,93,63318,DB00670,Pirenzepine
,8310710,renal clearance,"Its renal clearance averaged 6.65 ml/min per kg (350% of the creatinine clearance) in all subjects, 74% being due to net tubular secretion.",Renal clearance of pyridostigmine in myasthenic patients and volunteers under the influence of ranitidine and pirenzepine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310710/),[ml] / [kg·min],6.65,64883,DB00670,Pirenzepine
,8310710,elimination,5. Pyridostigmine had a higher elimination (2 h-1) than the absorption rate constant (0.23 h-1) when administered orally as a non-retarded preparation.,Renal clearance of pyridostigmine in myasthenic patients and volunteers under the influence of ranitidine and pirenzepine. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310710/),1/[h],2,64884,DB00670,Pirenzepine
,8310710,absorption rate constant,5. Pyridostigmine had a higher elimination (2 h-1) than the absorption rate constant (0.23 h-1) when administered orally as a non-retarded preparation.,Renal clearance of pyridostigmine in myasthenic patients and volunteers under the influence of ranitidine and pirenzepine. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310710/),1/[h],0.23,64885,DB00670,Pirenzepine
,8868291,distribution half-lives,"Both radioligands were cleared from the circulation with distribution half-lives of 17 and 14 sec and elimination half-lives of 17 and 40 min for [3H]AF-DX 116 and [3H]AF-DX 384, respectively.","In vivo binding, pharmacokinetics and metabolism of the selective M2 muscarinic antagonists [3H]AF-DX 116 and [3H]AF-DX 384 in the anesthetized rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8868291/),s,17,72789,DB00670,Pirenzepine
,8868291,distribution half-lives,"Both radioligands were cleared from the circulation with distribution half-lives of 17 and 14 sec and elimination half-lives of 17 and 40 min for [3H]AF-DX 116 and [3H]AF-DX 384, respectively.","In vivo binding, pharmacokinetics and metabolism of the selective M2 muscarinic antagonists [3H]AF-DX 116 and [3H]AF-DX 384 in the anesthetized rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8868291/),s,14,72790,DB00670,Pirenzepine
,8868291,elimination half-lives,"Both radioligands were cleared from the circulation with distribution half-lives of 17 and 14 sec and elimination half-lives of 17 and 40 min for [3H]AF-DX 116 and [3H]AF-DX 384, respectively.","In vivo binding, pharmacokinetics and metabolism of the selective M2 muscarinic antagonists [3H]AF-DX 116 and [3H]AF-DX 384 in the anesthetized rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8868291/),min,17,72791,DB00670,Pirenzepine
,8868291,elimination half-lives,"Both radioligands were cleared from the circulation with distribution half-lives of 17 and 14 sec and elimination half-lives of 17 and 40 min for [3H]AF-DX 116 and [3H]AF-DX 384, respectively.","In vivo binding, pharmacokinetics and metabolism of the selective M2 muscarinic antagonists [3H]AF-DX 116 and [3H]AF-DX 384 in the anesthetized rat. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8868291/),min,40,72792,DB00670,Pirenzepine
,2917592,t1/2 gamma,"In patients with renal and hepatic insufficiency, CL was reduced, t1/2 gamma was prolonged from 11.1 to 19.4 h and Cmin(ss) was elevated from 36 ng/ml to 66 ng/ml compared to healthy controls.",Steady-state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renal- and hepatic insufficiency. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917592/),h,11.1 to 19.4,79193,DB00670,Pirenzepine
,2917592,Cmin(ss),"In patients with renal and hepatic insufficiency, CL was reduced, t1/2 gamma was prolonged from 11.1 to 19.4 h and Cmin(ss) was elevated from 36 ng/ml to 66 ng/ml compared to healthy controls.",Steady-state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renal- and hepatic insufficiency. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917592/),[ng] / [ml],36,79194,DB00670,Pirenzepine
,2917592,Cmin(ss),"In patients with renal and hepatic insufficiency, CL was reduced, t1/2 gamma was prolonged from 11.1 to 19.4 h and Cmin(ss) was elevated from 36 ng/ml to 66 ng/ml compared to healthy controls.",Steady-state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renal- and hepatic insufficiency. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917592/),[ng] / [ml],66,79195,DB00670,Pirenzepine
,2751741,biological half-life,There was no significant difference in the biological half-life of pirenzepine between the two treatments (10.1-9.4 h).,Effect of an aluminium-hydroxide containing antacid on the oral bioavailability of pirenzepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751741/),h,10.1-9.4,98974,DB00670,Pirenzepine
,10511917,half-life,"Its mean half-life in healthy individuals was 33 hours, ranging from 21 to 54 hours.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),h,33,129674,DB00670,Pirenzepine
,10511917,apparent plasma clearance,"The mean apparent plasma clearance was 26 L/h, ranging from 12 to 47 L/h.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),[l] / [h],26,129675,DB00670,Pirenzepine
,12172335,area under the plasma concentration-time curve,Ritonavir reduced the area under the plasma concentration-time curve of olanzapine from 501 ng.,Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172335/),ng,501,143366,DB00670,Pirenzepine
,12172335,half-life,"hr/mL (197-294) (p < 0.001), the half-life from 32 hours (28-36) to 16 hours (14-18) (p = 0.00001), and the peak concentration from 15 ng/mL (13-19) to 9 ng/mL (8-12) (p = 0.002).",Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172335/),h,32,143367,DB00670,Pirenzepine
,12172335,half-life,"hr/mL (197-294) (p < 0.001), the half-life from 32 hours (28-36) to 16 hours (14-18) (p = 0.00001), and the peak concentration from 15 ng/mL (13-19) to 9 ng/mL (8-12) (p = 0.002).",Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172335/),h,16,143368,DB00670,Pirenzepine
,12172335,peak concentration,"hr/mL (197-294) (p < 0.001), the half-life from 32 hours (28-36) to 16 hours (14-18) (p = 0.00001), and the peak concentration from 15 ng/mL (13-19) to 9 ng/mL (8-12) (p = 0.002).",Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172335/),[ng] / [ml],15,143369,DB00670,Pirenzepine
,12172335,peak concentration,"hr/mL (197-294) (p < 0.001), the half-life from 32 hours (28-36) to 16 hours (14-18) (p = 0.00001), and the peak concentration from 15 ng/mL (13-19) to 9 ng/mL (8-12) (p = 0.002).",Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172335/),[ng] / [ml],9,143370,DB00670,Pirenzepine
,12172335,oral clearance,Olanzapine oral clearance increased from 20 L/hr (18-23) to 43 L/hr (38-51) (p < 0.001) after ritonavir.,Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172335/),[l] / [h],20,143371,DB00670,Pirenzepine
,12172335,oral clearance,Olanzapine oral clearance increased from 20 L/hr (18-23) to 43 L/hr (38-51) (p < 0.001) after ritonavir.,Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172335/),[l] / [h],43,143372,DB00670,Pirenzepine
,3790194,terminal elimination half-life,"Following i.v. administration, the terminal elimination half-life, t 1/2, the volume of distribution, V1, and the total plasma clearance Cl were determined to be 7.7 +/- 1.4 h, 0.255 +/- 0.057 l/kg and 263.4 +/- 56.8 ml/min, respectively.",Pharmacokinetics and bioequivalence of different formulations of pirenzepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790194/),h,7.7,148990,DB00670,Pirenzepine
,3790194,t 1/2,"Following i.v. administration, the terminal elimination half-life, t 1/2, the volume of distribution, V1, and the total plasma clearance Cl were determined to be 7.7 +/- 1.4 h, 0.255 +/- 0.057 l/kg and 263.4 +/- 56.8 ml/min, respectively.",Pharmacokinetics and bioequivalence of different formulations of pirenzepine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790194/),[l] / [kg],0.255,148991,DB00670,Pirenzepine
,3790194,"volume of distribution, V1","Following i.v. administration, the terminal elimination half-life, t 1/2, the volume of distribution, V1, and the total plasma clearance Cl were determined to be 7.7 +/- 1.4 h, 0.255 +/- 0.057 l/kg and 263.4 +/- 56.8 ml/min, respectively.",Pharmacokinetics and bioequivalence of different formulations of pirenzepine. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790194/),[l] / [kg],0.255,148992,DB00670,Pirenzepine
,3790194,total plasma clearance Cl,"Following i.v. administration, the terminal elimination half-life, t 1/2, the volume of distribution, V1, and the total plasma clearance Cl were determined to be 7.7 +/- 1.4 h, 0.255 +/- 0.057 l/kg and 263.4 +/- 56.8 ml/min, respectively.",Pharmacokinetics and bioequivalence of different formulations of pirenzepine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790194/),[ml] / [min],263.4,148993,DB00670,Pirenzepine
,3790194,systemic availabilities,"From the tablet and suspension formulation the systemic availabilities were calculated to be 33.5% and 20.3%, respectively.",Pharmacokinetics and bioequivalence of different formulations of pirenzepine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790194/),%,33.5,148994,DB00670,Pirenzepine
,3790194,systemic availabilities,"From the tablet and suspension formulation the systemic availabilities were calculated to be 33.5% and 20.3%, respectively.",Pharmacokinetics and bioequivalence of different formulations of pirenzepine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790194/),%,20.3,148995,DB00670,Pirenzepine
,2340846,f,"Mean f in the patients was 0.28, which was significantly higher than in 12 normal subjects (0.14).",Absolute bioavailability of pirenzepine in intensive care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340846/),,0.28,150118,DB00670,Pirenzepine
,2340846,f,"Mean f in the patients was 0.28, which was significantly higher than in 12 normal subjects (0.14).",Absolute bioavailability of pirenzepine in intensive care patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340846/),,0.14,150119,DB00670,Pirenzepine
,2344866,terminal half-life,"The harmonic mean terminal half-life for pirenzepine was 17.3 h in subjects with end stage renal disease, 18.0 h in subjects with moderate renal insufficiency and 14.7 h in subjects with mild renal dysfunction.","Oral pharmacokinetics of pirenzepine in patients with chronic renal insufficiency, failure, and maintenance haemodialysis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2344866/),h,17.3,153911,DB00670,Pirenzepine
,2344866,terminal half-life,"The harmonic mean terminal half-life for pirenzepine was 17.3 h in subjects with end stage renal disease, 18.0 h in subjects with moderate renal insufficiency and 14.7 h in subjects with mild renal dysfunction.","Oral pharmacokinetics of pirenzepine in patients with chronic renal insufficiency, failure, and maintenance haemodialysis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2344866/),h,18.0,153912,DB00670,Pirenzepine
,2344866,terminal half-life,"The harmonic mean terminal half-life for pirenzepine was 17.3 h in subjects with end stage renal disease, 18.0 h in subjects with moderate renal insufficiency and 14.7 h in subjects with mild renal dysfunction.","Oral pharmacokinetics of pirenzepine in patients with chronic renal insufficiency, failure, and maintenance haemodialysis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2344866/),h,14.7,153913,DB00670,Pirenzepine
,2344866,arterial to venous plasma pirenzepine ratio,The mean arterial to venous plasma pirenzepine ratio during hemodialysis was 1.29 (range 1.02-1.56).,"Oral pharmacokinetics of pirenzepine in patients with chronic renal insufficiency, failure, and maintenance haemodialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2344866/),,1.29,153914,DB00670,Pirenzepine
,12352274,concentrations,Fluvoxamine concentrations were 48 +/- 26 ng/mL on week 1 and 83 +/- 47 ng/mL on week 8.,Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352274/),ng,48,177424,DB00670,Pirenzepine
,9855322,Steady-state concentrations,"Steady-state concentrations of olanzapine (15.3 ng/ml), 10-N-glucuronide (4.9 ng/ml), and 4'-N-desmethyl olanzapine (2.5 ng/ml) were observed after olanzapine 10 mg once/day and were unaffected by coadministration of theophylline.",Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855322/),[ng] / [ml],15.3,189466,DB00670,Pirenzepine
,9855322,Steady-state concentrations,"Steady-state concentrations of olanzapine (15.3 ng/ml), 10-N-glucuronide (4.9 ng/ml), and 4'-N-desmethyl olanzapine (2.5 ng/ml) were observed after olanzapine 10 mg once/day and were unaffected by coadministration of theophylline.",Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855322/),[ng] / [ml],4.9,189467,DB00670,Pirenzepine
,9855322,Steady-state concentrations,"Steady-state concentrations of olanzapine (15.3 ng/ml), 10-N-glucuronide (4.9 ng/ml), and 4'-N-desmethyl olanzapine (2.5 ng/ml) were observed after olanzapine 10 mg once/day and were unaffected by coadministration of theophylline.",Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855322/),[ng] / [ml],2.5,189468,DB00670,Pirenzepine
,2610502,area under the concentration-time curve,"However, the antacid caused a significant (P less than 0.01) reduction in the gastrointestinal absorption of doxycycline (area under the concentration-time curve, 38.6 +/- 22.7 mg.h/liter, fasting; 6.0 +/- 3.2 mg.h/liter, with antacid), resulting in subtherapeutic levels of doxycycline.","Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610502/),[h·mg] / [l],38.6,198791,DB00670,Pirenzepine
,2610502,area under the concentration-time curve,"However, the antacid caused a significant (P less than 0.01) reduction in the gastrointestinal absorption of doxycycline (area under the concentration-time curve, 38.6 +/- 22.7 mg.h/liter, fasting; 6.0 +/- 3.2 mg.h/liter, with antacid), resulting in subtherapeutic levels of doxycycline.","Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610502/),[h·mg] / [l],6.0,198792,DB00670,Pirenzepine
,2051325,limit of detection,The limit of detection is approximately 0.1 ng/assay.,Determination of nuvenzepine in human plasma by a sensitive [3H]pirenzepine radioreceptor binding assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2051325/),[ng] / [assay],0.1,203394,DB00670,Pirenzepine
,2051325,Cmax,"The pharmacokinetic parameters obtained were (for 15 and 25 mg): Cmax, 64 and 131 ng/mL; AUC0-infinity, 851 and 1379 ng.h/mL; t1/2, 8.6 and 7.2 h.",Determination of nuvenzepine in human plasma by a sensitive [3H]pirenzepine radioreceptor binding assay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2051325/),[ng] / [ml],64,203395,DB00670,Pirenzepine
,2051325,Cmax,"The pharmacokinetic parameters obtained were (for 15 and 25 mg): Cmax, 64 and 131 ng/mL; AUC0-infinity, 851 and 1379 ng.h/mL; t1/2, 8.6 and 7.2 h.",Determination of nuvenzepine in human plasma by a sensitive [3H]pirenzepine radioreceptor binding assay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2051325/),[ng] / [ml],131,203396,DB00670,Pirenzepine
,2051325,AUC0-infinity,"The pharmacokinetic parameters obtained were (for 15 and 25 mg): Cmax, 64 and 131 ng/mL; AUC0-infinity, 851 and 1379 ng.h/mL; t1/2, 8.6 and 7.2 h.",Determination of nuvenzepine in human plasma by a sensitive [3H]pirenzepine radioreceptor binding assay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2051325/),[h·ng] / [ml],851,203397,DB00670,Pirenzepine
,2051325,AUC0-infinity,"The pharmacokinetic parameters obtained were (for 15 and 25 mg): Cmax, 64 and 131 ng/mL; AUC0-infinity, 851 and 1379 ng.h/mL; t1/2, 8.6 and 7.2 h.",Determination of nuvenzepine in human plasma by a sensitive [3H]pirenzepine radioreceptor binding assay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2051325/),[h·ng] / [ml],1379,203398,DB00670,Pirenzepine
,2051325,t1/2,"The pharmacokinetic parameters obtained were (for 15 and 25 mg): Cmax, 64 and 131 ng/mL; AUC0-infinity, 851 and 1379 ng.h/mL; t1/2, 8.6 and 7.2 h.",Determination of nuvenzepine in human plasma by a sensitive [3H]pirenzepine radioreceptor binding assay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2051325/),h,8.6,203399,DB00670,Pirenzepine
,2051325,t1/2,"The pharmacokinetic parameters obtained were (for 15 and 25 mg): Cmax, 64 and 131 ng/mL; AUC0-infinity, 851 and 1379 ng.h/mL; t1/2, 8.6 and 7.2 h.",Determination of nuvenzepine in human plasma by a sensitive [3H]pirenzepine radioreceptor binding assay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2051325/),h,7.2,203400,DB00670,Pirenzepine
,11073289,oral clearance,"The mean (+/- SD) oral clearance and elimination half-life of olanzapine were 51.5+/-61.6 l/h and 30.9+/-4.3 hours, respectively.",Disposition of olanzapine in Chinese schizophrenic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11073289/),[l] / [h],51.5,207781,DB00670,Pirenzepine
,11073289,elimination half-life,"The mean (+/- SD) oral clearance and elimination half-life of olanzapine were 51.5+/-61.6 l/h and 30.9+/-4.3 hours, respectively.",Disposition of olanzapine in Chinese schizophrenic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11073289/),h,30.9,207782,DB00670,Pirenzepine
,9152596,absolute bioavailability,"After oral administration, OLZ was well absorbed in dogs (absolute bioavailability of 73%) and to the extent of at least 55% in monkeys and 32% in mice.","Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),%,73,219858,DB00670,Pirenzepine
,9152596,absolute bioavailability,"After oral administration, OLZ was well absorbed in dogs (absolute bioavailability of 73%) and to the extent of at least 55% in monkeys and 32% in mice.","Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),%,55,219859,DB00670,Pirenzepine
,9152596,absolute bioavailability,"After oral administration, OLZ was well absorbed in dogs (absolute bioavailability of 73%) and to the extent of at least 55% in monkeys and 32% in mice.","Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),%,32,219860,DB00670,Pirenzepine
,9152596,terminal elimination half-life,The terminal elimination half-life of OLZ was relatively short in mice and monkeys (approximately 3 hr) and long in dogs (approximately 9 hr).,"Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),h,3,219861,DB00670,Pirenzepine
,9152596,terminal elimination half-life,The terminal elimination half-life of OLZ was relatively short in mice and monkeys (approximately 3 hr) and long in dogs (approximately 9 hr).,"Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152596/),h,9,219862,DB00670,Pirenzepine
,10770461,apparent mean oral clearance,Olanzapine pharmacokinetic evaluation gave an apparent mean oral clearance of 9.6 +/- 2.4 L/hr and a mean elimination half-life of 37.2 +/- 5.1 hours in these young patients.,Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10770461/),[l] / [h],9.6,221695,DB00670,Pirenzepine
,10770461,elimination half-life,Olanzapine pharmacokinetic evaluation gave an apparent mean oral clearance of 9.6 +/- 2.4 L/hr and a mean elimination half-life of 37.2 +/- 5.1 hours in these young patients.,Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10770461/),h,37.2,221696,DB00670,Pirenzepine
,6941374,terminal half-life of disposition,The mean terminal half-life of disposition was 11 hours.,An international pharmacokinetic study on pirenzepine following a single oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6941374/),h,11,222824,DB00670,Pirenzepine
,8738191,plasma elimination half-times,"The plasma elimination half-times for olanzapine and the two metabolites were approximately the same, ranging from 3.3 to 4.4 h.",Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738191/),h,3.3 to 4.4,234362,DB00670,Pirenzepine
,9638310,tmax,This study demonstrated that [14C]olanzapine and/or metabolites were rapidly absorbed and widely distributed with a tmax of 2 h postdose in most tissues.,Disposition of the novel anti-schizophrenic drug [14C]olanzapine in male Fischer 344 and female CD rats following single oral dose administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638310/),h,2,248868,DB00670,Pirenzepine
,9638310,tmax,The placental transfer studies indicated that all tissues analyzed had a tmax of 1 or 3 h postdose with maternal liver consistently containing high concentrations of radiocarbon.,Disposition of the novel anti-schizophrenic drug [14C]olanzapine in male Fischer 344 and female CD rats following single oral dose administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638310/),h,1,248869,DB00670,Pirenzepine
,9638310,tmax,The placental transfer studies indicated that all tissues analyzed had a tmax of 1 or 3 h postdose with maternal liver consistently containing high concentrations of radiocarbon.,Disposition of the novel anti-schizophrenic drug [14C]olanzapine in male Fischer 344 and female CD rats following single oral dose administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638310/),h,3,248870,DB00670,Pirenzepine
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,24.2,260824,DB00670,Pirenzepine
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,10.3,260825,DB00670,Pirenzepine
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,75.2,260826,DB00670,Pirenzepine
,11920159,plasma elimination half-lives,"Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D(2) receptor occupancy.",Significant dissociation of brain and plasma kinetics with antipsychotics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920159/),h,66.6,260827,DB00670,Pirenzepine
,11699614,CLoral,"Moreover, there were no significant differences in any of the olanzapine pharmacokinetic parameters between the CYP2D6 PMs and EMs (CLoral=0.246 l h(-1) kg(-1) and 0.203 l h(-1) kg(-1), respectively, P=0.30).",Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699614/),[l] / [h·kg],0.246,261045,DB00670,Pirenzepine
,11699614,CLoral,"Moreover, there were no significant differences in any of the olanzapine pharmacokinetic parameters between the CYP2D6 PMs and EMs (CLoral=0.246 l h(-1) kg(-1) and 0.203 l h(-1) kg(-1), respectively, P=0.30).",Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699614/),[l] / [h·kg],0.203,261046,DB00670,Pirenzepine
greater,11254198,extraction efficiencies,The extraction efficiencies of olanzapine and internal standard (LY170158) were greater than 82% in brain tissue.,Quantitative determination of olanzapine in rat brain tissue by high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11254198/),%,82,261752,DB00670,Pirenzepine
,2085337,maximal plasma level (cmax),Following a single oral dose of 3 mg telenzepine the mean maximal plasma level (cmax) averaged 5.7 (1.9-10.1) ng/ml.,[Pharmacokinetics and tolerability of telenzepine in patients with compensated liver cirrhosis]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2085337/),[ng] / [ml],5.7,264784,DB00670,Pirenzepine
,3675700,elimination half-life (t1/2 beta),"2. With a dose of 50 mg of pirenzepine, plasma levels reached a maximum 2 h after the administration in both groups (gastric ulcer patients: 57.2 +/- 31.8 ng/ml, duodenal ulcer patients: 48.0 +/- 18.0 ng/ml), and decreased bi-phasically with an elimination half-life (t1/2 beta) of 13.9 +/- 4.0 and 17.9 +/- 4.5 h, respectively.",Pharmacokinetics of pirenzepine in patients with gastric or duodenal ulcers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675700/),h,13.9,268240,DB00670,Pirenzepine
,3675700,elimination half-life (t1/2 beta),"2. With a dose of 50 mg of pirenzepine, plasma levels reached a maximum 2 h after the administration in both groups (gastric ulcer patients: 57.2 +/- 31.8 ng/ml, duodenal ulcer patients: 48.0 +/- 18.0 ng/ml), and decreased bi-phasically with an elimination half-life (t1/2 beta) of 13.9 +/- 4.0 and 17.9 +/- 4.5 h, respectively.",Pharmacokinetics of pirenzepine in patients with gastric or duodenal ulcers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675700/),h,17.9,268241,DB00670,Pirenzepine
,3675700,area under the plasma level curve,The area under the plasma level curve were 844 +/- 319 ng X h/ml and 663 +/- 151 ng X h/ml in the respective group.,Pharmacokinetics of pirenzepine in patients with gastric or duodenal ulcers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675700/),[h·ng] / [ml],844,268242,DB00670,Pirenzepine
,3675700,area under the plasma level curve,The area under the plasma level curve were 844 +/- 319 ng X h/ml and 663 +/- 151 ng X h/ml in the respective group.,Pharmacokinetics of pirenzepine in patients with gastric or duodenal ulcers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675700/),[h·ng] / [ml],663,268243,DB00670,Pirenzepine
